Testing blood markers to predict graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- You are currently admitted to the hospital
- You are receiving an allogeneic stem cell transplant (using stem cells from another person)
- The transplant is for treatment of a cancer (malignant disease)
- You are planned for this transplant as an inpatient
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This study is testing a blood test called AlloHeme that may help doctors predict whether your blood cancer will come back after a stem cell transplant. Joining this study could help you and your doctor monitor your recovery more closely.
Hear when a new GVHD,Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.